IP Library Granted Patent US 8,003,389
Granted Patent B2
US 8,003,389 · App. 11/595,448 · Granted Aug 23, 2011

Buffer solution for electroporation and a method comprising the use of the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,003,389
App. No.
11/595,448
Granted
Aug 23, 2011
Kind
B2
Abstract

A method for introducing biologically active molecules into animal or human cells using electric current includes suspending the cells and dissolving the biologically active molecules in a buffer solution which has a buffer capacity of at least 20 mmol×l −1 ×pH −1 and an ionic strength of at least 200 mmol×l −1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C. to form a suspension. The method further includes applying an electric voltage to the suspension so as to introduce the biologically active molecules into animal or human cells.

Claims (18)

1. A method for introducing biologically active molecules into animal or human cells by means of electric current, comprising:

i. suspending the cells and dissolving the biologically active molecules in a buffer solution which has a buffer capacity of at least 20 mmol×l −1 ×pH −1 and an ionic strength of at least 200 mmol×l −1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C. to form a suspension, wherein the buffer solution comprises a concentration of potassium ions (K + ) between 2 and 6 mmol×l −1 K + , a concentration of sodium ions (Na + ) between 100 and 150 mmol×l −1 Na + and at least 10 mmol×l −1 magnesium ions (Mg 2+ ); and

ii. applying an electric voltage to the suspension so as to introduce said biologically active molecules into animal or human cells.

2. The method of claim 1 , wherein the buffer solution has a buffer capacity between 22 and 80 mmol×l −1 ×pH −1 .

3. The method of claim 1 , wherein the buffer solution has a buffer capacity between 40 and 70 mmol×l −1 ×pH −1 .

4. The method of claim 1 , wherein the buffer solution has an ionic strength between 200 and 500 mmol×l −1 .

5. The method of claim 1 , wherein the buffer solution has an ionic strength between 250 and 400 mmol×l −1 .

6. The method of claim 1 , wherein the buffer solution contains 15 to 20 mmol×l −1 magnesium ions.

7. The method of claim 1 , wherein the buffer solution contains magnesium chloride (MgCl 2 ) and/or magnesium sulphate (MgSO 4 ).

8. The method of claim 1 , wherein the buffer solution contains HEPES and/or Na 2 HPO 4 /NaH 2 PO 4 and/or Tris/HCl and/or K 2 HPO 4 /KH 2 PO 4 .

9. The method of claim 1 , wherein the buffer solution contains a compound selected from the group consisting of sodium chloride, sodium succinate, mannitol, glucose, sodium lactobionate and/or peptides.

10. The method of claim 1 , wherein the introduction of the biologically active molecules into the cells is achieved by a voltage pulse having a field strength of 2 to 10 kV×cm −1 and a duration of 10 to 200 μs and a current density of at least 2 A×cm −2 .

11. The method of claim 10 , wherein the introduction of the biologically active molecules into the cells is achieved by a current flow following said high-voltage pulse without interruption, having a current density of 2 to 14 A×cm −2 , and a duration of 1 to 100 ms.

12. The method of claim 10 , wherein the biologically active molecules are transfected into the cell nucleus of animal or human cells by means of electric current.

13. The method of claim 1 , wherein nucleic acids, proteins or peptides are introduced into quiescent or dividing animal or human cells.

14. The method of claim 1 , wherein nucleic acids, proteins or peptides are introduced into primary animal or human cells.

15. The method of claim 13 , wherein the nucleic acids are present in complexes or in compounds with peptides, proteins or other biologically active molecules.

16. The method of claim 1 , wherein the cells are selected from the group consisting of primary human blood cells, pluripotent precursor cells of human blood, primary human fibroblasts, endothelial cells, muscle cells and melanocytes.

Assignments (3)
CHANGE OF LEGAL FORM Recorded May 13, 2011
From: LONZA COLOGNE AG
To: LONZA COLOGNE GMBH
Reel/Frame 026276/0125 →
CHANGE OF LEGAL FORM Recorded Feb 3, 2011
From: LONZA COLOGNE AG
To: LONZA COLOGNE GMBH
Reel/Frame 025741/0888 →
CHANGE OF NAME Recorded Jun 18, 2009
From: AMAXA AG
To: LONZA COLOGNE AG
Reel/Frame 022846/0012 →